CVS Health (NYSE:CVS) Shares Climb 3.1% - Time to Buy?

Key Points

• CVS shares rose 3.1% to about $89, though trading volume was significantly below average. The move follows an improved outlook for its Health Care Benefits segment, supported by stronger Medicare trends and anticipated margin recovery.
• Analysts remain broadly bullish, with a “Moderate Buy” consensus and an average price target of $107.24; several firms have issued targets between $110 and $123. CVS also recently exceeded earnings and revenue expectations and reaffirmed fiscal 2026 EPS guidance of $7.90–$8.10.
• Medical-cost inflation remains the main risk to the turnaround and could slow margin improvement. The company pays a $0.665 quarterly dividend, equivalent to a 3.0% yield, while institutional investors own about 80.7% of its shares.

CVS Health Corporation (NYSE:CVS - Get Free Report) was up 3.1% on Wednesday. The company traded as high as $88.82 and last traded at $89.1440. Approximately 919,503 shares traded hands during mid-day trading, a decline of 89% from the average daily volume of 8,265,509 shares. The stock had previously closed at $86.43.

Key CVS Health News

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: CVS raised its outlook for the Health Care Benefits segment as stronger Medicare trends support expected margin recovery. Medical-cost pressures remain a concern, but the improved core trends are a significant catalyst for the stock. CVS' Health Care Benefits Arm Shows Better Core Trends: What's Ahead?
• Positive Sentiment: Commentary highlighted CVS as significantly undervalued, suggesting that much of the company’s negative news may already be reflected in its share price and leaving room for a recovery if operations improve. Why CVS Is ‘Insanely Cheap'
• Positive Sentiment: Analysts have a consensus price target of $107.24, well above the reported trading level, providing a bullish valuation signal if CVS executes against its earnings and margin-recovery plans. CVS Health Corporation Stock Has Consensus Price Target of $107.24
• Positive Sentiment: Analyst research points to CVS’s history of earnings surprises and favorable conditions for another beat in the upcoming report, supporting investor expectations for continued earnings momentum. Will CVS Health Beat Estimates Again?
• Neutral Sentiment: CVS opened its first pharmacy-focused location in the Boston area as part of a strategy to improve access to pharmacy care. The initiative may strengthen local service delivery, but its near-term financial impact is unclear. CVS Pharmacy Celebrates Opening of First Pharmacy-Focused Location
• Neutral Sentiment: CVS is promoting MMR vaccinations at more than 530 New York pharmacies and MinuteClinic locations amid a measles outbreak. The announcement reinforces CVS’s healthcare-access role but is unlikely to materially affect near-term earnings. CVS Health Reminds New Yorkers About MMR Vaccines
• Neutral Sentiment: CVS announced a $5 million scholarship donation to the University of Louisiana Monroe College of Pharmacy. The move supports workforce development and community relations but carries no immediate earnings benefit.
• Negative Sentiment: Medical-cost inflation remains the principal risk identified in coverage of the Health Care Benefits segment, potentially limiting the pace of margin improvement despite the raised outlook.

Analyst Ratings Changes

Several brokerages recently commented on CVS. Wells Fargo & Company boosted their price target on CVS Health from $103.00 to $123.00 and gave the company an "overweight" rating in a research note on Monday, July 13th. UBS Group restated a "buy" rating on shares of CVS Health in a report on Tuesday, September 22nd. Piper Sandler set a $112.00 price target on CVS Health in a report on Wednesday, September 9th. Bank of America raised their target price on shares of CVS Health from $100.00 to $110.00 and gave the company a "buy" rating in a research note on Monday, June 22nd. Finally, BMO Capital Markets set a $112.00 target price on shares of CVS Health in a research report on Wednesday, September 9th. Twenty-two investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to MarketBeat.com, CVS Health presently has a consensus rating of "Moderate Buy" and an average price target of $107.24.

CVS Health Trading Up 3.4%

The company has a current ratio of 0.87, a quick ratio of 0.66 and a debt-to-equity ratio of 0.74. The stock has a market capitalization of $114.25 billion, a P/E ratio of 23.62, a P/E/G ratio of 0.85 and a beta of 0.60. The business's fifty day simple moving average is $93.81 and its two-hundred day simple moving average is $92.19.

CVS Health (NYSE:CVS - Get Free Report) last posted its quarterly earnings data on Wednesday, August 5th. The pharmacy operator reported $2.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.87 by $0.71. CVS Health had a net margin of 1.18% and a return on equity of 13.12%. The company had revenue of $106.10 billion for the quarter, compared to the consensus estimate of $100.03 billion. During the same quarter in the previous year, the firm posted $1.81 EPS. The business's revenue was up 7.3% compared to the same quarter last year. CVS Health has set its FY 2026 guidance at 7.900-8.100 EPS. As a group, analysts forecast that CVS Health Corporation will post 8.02 earnings per share for the current year.

CVS Health Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, November 2nd. Stockholders of record on Thursday, October 22nd will be issued a dividend of $0.6650 per share. This represents a $2.66 annualized dividend and a dividend yield of 3.0%. The ex-dividend date of this dividend is Thursday, October 22nd. CVS Health's dividend payout ratio (DPR) is presently 70.37%.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. BlackRock Inc. bought a new stake in CVS Health in the second quarter valued at about $12,747,462,000. State Street Corp grew its stake in shares of CVS Health by 26.3% in the 2nd quarter. State Street Corp now owns 74,927,064 shares of the pharmacy operator's stock valued at $7,751,205,000 after purchasing an additional 15,604,883 shares during the period. Wellington Management Group LLP raised its holdings in shares of CVS Health by 49.8% in the 2nd quarter. Wellington Management Group LLP now owns 33,801,113 shares of the pharmacy operator's stock worth $3,496,725,000 after buying an additional 11,233,381 shares in the last quarter. Bank of America Corp DE lifted its position in shares of CVS Health by 148.0% during the 2nd quarter. Bank of America Corp DE now owns 23,188,670 shares of the pharmacy operator's stock worth $2,398,868,000 after buying an additional 13,836,701 shares during the period. Finally, Pzena Investment Management LLC acquired a new stake in CVS Health in the 2nd quarter valued at $1,217,558,000. 80.66% of the stock is owned by institutional investors.

CVS Health Company Profile

CVS Health Corp. is an integrated health care company that provides pharmacy, insurance and health services primarily in the United States. Its operations are designed to connect consumers, health plans, health care providers and pharmacy services across multiple points of care.

The company's major businesses include CVS Pharmacy retail locations, prescription fulfillment and consumer health products; CVS Caremark, a pharmacy benefit management business; and Aetna, which offers health insurance products and related services for employers, individuals, government programs and other organizations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.